Sequential evaluation of serum hepcidin in anemic myeloma patients: Study of correlations with myeloma treatment, disease variables, and anemia response

American Journal of Hematology

Volumn 84, Issue 8, 2009, Pages 524-526

  Katodritou, Eirini ^a   Ganz, Tomas ^b   Terpos, Evangelos ^c   Verrou, Evgenia ^a   Olbina, Gordana ^d   Gastari, Vassiliki ^a   Hadjiaggelidou, Christina ^a   Varthaliti, Maria ^a   Georgiadou, Sofia ^a   Westerman, Mark ^d   Zervas, Konstantinos ^a  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d Intrinsic LifeSciences LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; HEMOGLOBIN; HEPCIDIN; IMMUNOGLOBULIN M; IMMUNOMODULATING AGENT; TRANSFERRIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SCORING SYSTEM; THROMBOCYTE; TREATMENT RESPONSE;

ADULT; AGED; ANEMIA; ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL MARKERS; BLOOD PROTEINS; COHORT STUDIES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IRON; MALE; MIDDLE AGED; MULTIPLE MYELOMA;

EID: 67749091257     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21448     Document Type: Article

References (21)

1. Kyle RA. Multiple myeloma: Review of 869 cases. Mayo Clin Proc 1975;50:29-40.
2. Harper P, Littlewood T. Anemia of cancer: Impact on patient fatigue and long-term outcome. Oncology 2005;69:2-7. (Pubitemid 41507248)
3. Goodnough L. Erythropoietin and iron-restricted erythropoiesis. Exp Hematol 2007;35:167-172.
4. Weiss G, Goodnough L. Anemia of chronic disease. N Engl J Med 2005;352:1011-1023.
5. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001;276:7806-7810. (Pubitemid 37385573)
6. Ganz T. Hepcidin and its role in regulating systemic iron metabolism. Hematol Am Soc Hematol Educ Program 2006;507:29-35.
7. Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M. Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis. Am J Hematol 2006;81:832-837. (Pubitemid 44682184)
8. Katodritou E, Verrou E, Zervas K. Intravenous iron: A useful therapeutic tool but not a panacea. Am J Hematol 2008;83:521-523. (Pubitemid 351874865)
9. Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute phase protein. Blood 2003;101:2461-2463. (Pubitemid 36857598)
10. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-1276. (Pubitemid 39069926)
11. Truksa J, Peng H, Lee P, Beutler E. Different regulatory elements are required for response of hepcidin to interleukin-6 and bone morphogenetic proteins 4 and 9. Br J Haematol 2007;139:138-147. (Pubitemid 47389916)
12. Kurata M, Nakagawa Y, Yamamoto K, et al. Induction of integrin beta1 expression in bone marrow cells after chemotherapy correlates with the overexpression of lung resistance protein and poor outcome in patients with multiple myeloma. Am J Hematol 2008;83:755-757.
13. Yasui H, Hideshima T, Richardson PG, Anderso KC. Novel strategies targeting growth factor signaling cascades in multiple myeloma. Br J Haematol 2006;132:385-397. (Pubitemid 43381614)
14. Sharma S, Nemeth E, Chen YH, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res 2008;14:3262-3267.
15. Palumbo A, Facon T, Sonneveld P, et al. Thaldomide for treatment of multiple myeloma: 10 years later. Blood 2008;111:3968-3977.
16. Palumbo A, Miguel JS, Sonneveld P, et al. Lenalidomide, a new therapy for multiple myeloma. Cancer Treat Rev 2008;34:283-291.
17. Teo ST. Properties of thalidomide and its analogues: Implications for anticancer therapy. AAPS J 2005;7:14-19.
18. Grzasko N, Dmoszynska A, Hus M, et al. Stimulation of erythropoiesis by thalidomide in multiple myeloma patients: Its influence on FasL, TRAIL and their receptors on erythroblasts. Haematologica 2006;91:386-389.
19. Palumbo A, San Miguel J, Sonneveld P, et al. Lenalidomide: A new therapy for multiple myeloma. Cancer Treat Rev 2008;34:283-291.
20. Katodritou E, Verrou E, Hadjiaggelidou C, et al. Erythropoiesis stimulating agents are associated with reduced survival in patients with multiple myeloma. Am J Hematol 2008;83:697-701.
21. Ganz T, Olbina G, Girelli D, et al. Immunoassay for human serum hepcidin. Blood 2008;112:4292-4297.